Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Duality Biotherapeutics's operating assets for the quarter that ended in Jun. 2026 was €51.9 Mil. Duality Biotherapeutics's operating liabilities for the quarter that ended in Jun. 2026 was €215.5 Mil. Duality Biotherapeutics's Total Assets for the quarter that ended in Dec. 2025 was €474.3 Mil. Therefore, Duality Biotherapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was -0.34.
Duality Biotherapeutics Scaled Net Operating Assets Related Terms
Duality Biotherapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Duality Biotherapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics Scaled Net Operating Assets Chart
Duality Biotherapeutics Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Scaled Net Operating Assets
-0.15
-0.33
-0.28
-0.37
Duality Biotherapeutics Semi-Annual Data
Jun25
Dec25
Jun26
Scaled Net Operating Assets
-0.41
-0.21
-0.34
FRA:4ZB vs VRTX, REGN, MRNA: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Duality Biotherapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.34 mean?
Duality Biotherapeutics (FRA:4ZB) has a Scaled Net Operating Assets of -0.34 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Scaled Net Operating Assets too high?
Duality Biotherapeutics' current Scaled Net Operating Assets is -0.34. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Scaled Net Operating Assets compare to VRTX and REGN?
Duality Biotherapeutics' Scaled Net Operating Assets of -0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Scaled Net Operating Assets is -0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Scaled Net Operating Assets of -0.34. The current Scaled Net Operating Assets is -0.34. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Scaled Net Operating Assets is -0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score
Get the complete analysis for FRA:4ZB
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4ZB has been successfully added to your 
